SHL Telemedicine Ltd
SIX:SHLTN
Intrinsic Value
SHL Telemedicine Ltd. engages in the development and market of advanced personal telemedicine solutions, which focuses on cardiovascular and related diseases. [ Read More ]
The intrinsic value of one
SHLTN
stock under the Base Case scenario is
6.21
CHF.
Compared to the current market price of 3.7 CHF,
SHL Telemedicine Ltd
is
Undervalued by 40%.
SHL Telemedicine Ltd's market capitalization is 60.6m CHF.
SHLTN stock price is 3.7 CHF.
SHLTN stock price (3.7 CHF) is 40% less than its Intrinsic Value (6.21 CHF).
SHLTN stock price (3.7 CHF) is 68% less than its Relative Value (11.49 CHF). Open Relative Valuation
SHLTN has upside potential of 184% compared to the average analyst price target.
Open Wall St Estimates
SHLTN's Revenue has dropped by 3% over the past 12 months.
SHLTN's Revenue has been growing by 12% per year for the last 3 years.
SHLTN's ROE (Return on Equity) has significantly decreased in the last 3 years from 1% to -11%.
SHLTN's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 3% to -10%.
SHLTN's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -10%.
SHLTN's ROE (Return on Equity) for the past 12 months is negative and is equal to -11%.
SHLTN has negative Operating Income for the last twelve months.
SHLTN has negative Net Debt. This means that the company has more cash and short-term investments (26m USD) than debt (15m USD).
SHLTN has negative Net Income for the last twelve months.
SHLTN's short-term assets (40m USD) exceed its short-term liabilties (17m USD).
SHLTN has positive Gross Profit for the last twelve months.
SHLTN has negative Free Cash Flow for the last twelve months.
SHLTN has negative three-year average ROIC (Return on Invested Capital): -8%. The company is not efficient at using invested capital to generate operating income.
SHLTN's long-term assets (113m USD) exceed its long-term liabilties (40m USD).
SHLTN has negative three-year average ROE (Return on Equity): -10%. The company is not efficient at transforming stockholders' equity into net income.
SHLTN's D/E (Debt to Equity) is very low and is equal to 0.21.
SHLTN's Altman Z-Score is very low and is equal to 0.98.
SHLTN doesn't generate enough operating income (-8m USD) to safely cover interest payments on its debt (1m USD).
Valuation Backtest
SHL Telemedicine Ltd
Run backtest to discover the historical profit from buying and selling
SHLTN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
SHL Telemedicine Ltd
Balance Sheet Decomposition
SHL Telemedicine Ltd
| Current Assets | 40.1m |
| Cash & Short-Term Investments | 26.3m |
| Receivables | 10.3m |
| Other Current Assets | 3.5m |
| Non-Current Assets | 73m |
| Long-Term Investments | 328k |
| PP&E | 12.1m |
| Intangibles | 53.2m |
| Other Non-Current Assets | 7.3m |
| Current Liabilities | 17.4m |
| Accounts Payable | 3.9m |
| Other Current Liabilities | 13.6m |
| Non-Current Liabilities | 22.1m |
| Long-Term Debt | 15.3m |
| Other Non-Current Liabilities | 6.8m |
Earnings Waterfall
SHL Telemedicine Ltd
|
Revenue
|
57.1m
USD
|
|
Cost of Revenue
|
-31.8m
USD
|
|
Gross Profit
|
25.3m
USD
|
|
Operating Expenses
|
-33m
USD
|
|
Operating Income
|
-7.8m
USD
|
|
Other Expenses
|
715k
USD
|
|
Net Income
|
-7.1m
USD
|
Free Cash Flow Analysis
SHL Telemedicine Ltd
SHLTN Profitability Score
Profitability Due Diligence
SHL Telemedicine Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
SHL Telemedicine Ltd's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
SHLTN Solvency Score
Solvency Due Diligence
SHL Telemedicine Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
SHL Telemedicine Ltd's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SHLTN Price Targets Summary
SHL Telemedicine Ltd
According to Wall Street analysts, the average 1-year price target for
SHLTN
is 10.5 CHF
.
Shareholder Return
SHLTN Price
SHL Telemedicine Ltd
| Average Annual Return | 38.7% |
| Standard Deviation of Annual Returns | 65.01% |
| Max Drawdown | -82% |
| Market Capitalization | 60.6m CHF |
| Shares Outstanding | 16 391 428 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
SHL Telemedicine Ltd
Country
Industry
Market Cap
Dividend Yield
Description
SHL Telemedicine Ltd. engages in the development and market of advanced personal telemedicine solutions, which focuses on cardiovascular and related diseases. Personal telemedicine is the transmission of medical data by an individual, from a remote location, to a medical call center through telecommunication networks. SHL’s platform offers solutions to subscribing patients, health insurance companies, hospitals, clinics, physicians and other health care providers. Its solutions for healthcare professionals include: CHF monitoring service that supports patients suffering from Congestive Heart Failure; COPD monitoring service that supports patients suffering from Chronic Obstructive Pulmonary Disease, and Readmission Solutions for reducing heart-related readmissions. Its consumers' solutions include Cardiac Monitoring Service.
Contact
IPO
Employees
Officers
The intrinsic value of one
SHLTN
stock under the Base Case scenario is
6.21
CHF.
Compared to the current market price of 3.7 CHF,
SHL Telemedicine Ltd
is
Undervalued by 40%.
You don't have any saved screeners yet
